MCID: LNG115
MIFTS: 50

Lung Sarcomatoid Carcinoma

Categories: Cancer diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lung Sarcomatoid Carcinoma

MalaCards integrated aliases for Lung Sarcomatoid Carcinoma:

Name: Lung Sarcomatoid Carcinoma 11 14 16
Sarcomatoid Carcinoma of the Lung 11 75
Pulmonary Sarcomatoid Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:0080777
NCIt 49 C45540

Summaries for Lung Sarcomatoid Carcinoma

Disease Ontology: 11 A lung carcinoma that is characterized by the presence of a sarcomatoid component often associated with giant cell differentiation.

MalaCards based summary: Lung Sarcomatoid Carcinoma, also known as sarcomatoid carcinoma of the lung, is related to pulmonary blastoma and small cell cancer of the lung. An important gene associated with Lung Sarcomatoid Carcinoma is KDM4C (Lysine Demethylase 4C), and among its related pathways/superpathways are Signal Transduction and RAF/MAP kinase cascade. The drugs Durvalumab and Tremelimumab have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and spinal cord, and related phenotypes are Decreased viability and neoplasm

Wikipedia: 75 Sarcomatoid carcinoma of the lung is a term that encompasses five distinct histological subtypes of lung... more...

Related Diseases for Lung Sarcomatoid Carcinoma

Diseases related to Lung Sarcomatoid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 451)
# Related Disease Score Top Affiliating Genes
1 pulmonary blastoma 30.9 NKX2-1 KRAS EGFR
2 small cell cancer of the lung 30.8 NKX2-1 KRT7 EGFR
3 sarcomatoid mesothelioma 30.4 KRT5 CALB2
4 bronchus cancer 30.3 KRT7 EGFR ALK
5 carcinosarcoma 30.2 KRT7 KRAS HRAS EGFR CD274 CALB2
6 angiosarcoma 30.2 ROS1 KRAS CALB2
7 benign mesothelioma 30.2 NKX2-1 KRT7 KRT5 CALB2
8 appendix adenocarcinoma 30.2 KRT7 KRAS HRAS
9 exanthem 30.1 KRAS HRAS EGFR CD274 ALK
10 lung squamous cell carcinoma 29.9 KRAS HRAS EGFR CD274 ALK
11 blastoma 29.9 RET NKX2-1 KRT7 KRAS HRAS EGFR
12 lung giant cell carcinoma 29.9 NKX2-1 NAPSA KRT7 KRT5 KRAS EGFR
13 small intestine cancer 29.8 KRT7 KRAS HRAS EGFR CD274
14 pleural disease 29.8 KRT5 EGFR CD274 CALB2 ALK
15 leukemia, chronic lymphocytic 29.7 KRAS KDM4C HRAS EGFR CD274 ALK
16 leukemia, acute myeloid 29.7 KRAS KDM4C HRAS EGFR CD274 ALK
17 mesothelioma, malignant 29.6 NKX2-1 MET KRT7 KRT5 CALB2
18 malignant pleural mesothelioma 29.6 MET HRAS EGFR CD274 CALB2
19 squamous cell carcinoma 29.5 NKX2-1 KRT7 KRAS KDM4C HRAS EGFR
20 small cell carcinoma 29.5 NKX2-1 NAPSA KRT7 KRT5 EGFR ALK
21 mixed cell type cancer 29.5 KRT7 KRT5 KRAS HRAS EGFR CALB2
22 sarcoma 29.4 ROS1 MET KRAS HRAS CALB2 ALK
23 lung benign neoplasm 29.4 NKX2-1 MET KRT7 KRAS HRAS EGFR
24 adenosquamous carcinoma 29.3 NKX2-1 KRT7 KRT5 KRAS HRAS EGFR
25 mucinous adenocarcinoma 29.2 ROS1 NKX2-1 NAPSA KRT7 KRAS HRAS
26 rhabdomyosarcoma 29.0 RET MET KRT7 KRAS HRAS EGFR
27 pleomorphic carcinoma 28.9 ROS1 NKX2-1 NAPSA KRT7 KRT5 KRAS
28 wilms tumor 1 28.8 NKX2-1 KRT7 KRT5 KRAS KDM4C HRAS
29 large cell neuroendocrine carcinoma 28.7 ROS1 NKX2-1 NAPSA KRT7 KRT5 KRAS
30 large cell carcinoma 28.4 ROS1 NKX2-1 NAPSA KRT7 KRT5 KRAS
31 lung cancer susceptibility 3 28.3 ROS1 NKX2-1 NAPSA MET KRT7 KRAS
32 adenocarcinoma 28.2 ROS1 RET NKX2-1 NAPSA MET KRT7
33 lung cancer 28.0 ROS1 RET NKX2-1 NAPSA MET KRT7
34 renal cell carcinoma, nonpapillary 27.9 RET NKX2-1 NAPSA MET KRT7 KRAS
35 pleuropulmonary blastoma 10.4
36 lung sarcoma 10.4 CALB2 ALK
37 fibrous histiocytoma 10.4
38 cutaneous fibrous histiocytoma 10.4
39 pulmonary plasma cell granuloma 10.3 ROS1 ALK
40 heart leiomyosarcoma 10.3 EGFR ALK
41 urethra transitional cell carcinoma 10.3 EGFR ALK
42 malignant giant cell tumor of the tendon sheath 10.3 ROS1 ALK
43 gray zone lymphoma 10.3 KDM4C CD274
44 benign fibrous mesothelioma 10.3 CALB2 ALK
45 liver leiomyoma 10.3 CALB2 ALK
46 trachea carcinoma in situ 10.3 KRAS HRAS
47 malignant fibrous histiocytoma 10.3
48 fibrosarcoma 10.3
49 common bile duct neoplasm 10.3 KRAS HRAS
50 composite lymphoma 10.3 KDM4C CD274

Graphical network of the top 20 diseases related to Lung Sarcomatoid Carcinoma:



Diseases related to Lung Sarcomatoid Carcinoma

Symptoms & Phenotypes for Lung Sarcomatoid Carcinoma

GenomeRNAi Phenotypes related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

25 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.78 EGFR HRAS KRAS
2 Decreased viability GR00055-A-2 9.78 EGFR HRAS KRAS
3 Decreased viability GR00055-A-3 9.78 KRAS
4 Decreased viability GR00106-A-0 9.78 KRAS
5 Decreased viability GR00221-A-1 9.78 ALK EGFR HRAS KRAS RET ROS1
6 Decreased viability GR00221-A-2 9.78 HRAS KRAS RET ROS1
7 Decreased viability GR00221-A-3 9.78 HRAS
8 Decreased viability GR00221-A-4 9.78 ALK EGFR RET
9 Decreased viability GR00249-S 9.78 ALK ROS1
10 Decreased viability GR00301-A 9.78 KRAS RET
11 Decreased viability GR00342-S-1 9.78 ROS1
12 Decreased viability GR00381-A-1 9.78 KRAS
13 Decreased viability GR00402-S-2 9.78 RET

MGI Mouse Phenotypes related to Lung Sarcomatoid Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.92 ALK EGFR HRAS KDM4C KRAS MET
2 normal MP:0002873 9.86 ALK CALB2 EGFR HRAS KRAS MET
3 no phenotypic analysis MP:0003012 9.81 CD274 EGFR HRAS KDM4C KRAS MET
4 digestive/alimentary MP:0005381 9.5 EGFR HRAS KRAS KRT5 MET NKX2-1
5 respiratory system MP:0005388 9.17 ALK EGFR HRAS KRAS MET NKX2-1

Drugs & Therapeutics for Lung Sarcomatoid Carcinoma

Drugs for Lung Sarcomatoid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Durvalumab Approved, Investigational Phase 2 1428935-60-7
2
Tremelimumab Approved, Investigational Phase 2 745013-59-6
3
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
4
Ifosfamide Approved Phase 2 3778-73-2 3690
5
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
6
Nivolumab Approved Phase 2 946414-94-4
7
Ipilimumab Approved Phase 2 477202-00-9
8
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
9
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
10
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
11
Palifosfamide Investigational Phase 2 31645-39-3 100427
12 Anti-Bacterial Agents Phase 2
13 Alkylating Agents Phase 2
14 Antineoplastic Agents, Alkylating Phase 2
15 Antibiotics, Antitubercular Phase 2
16 Liposomal doxorubicin Phase 2
17 Immunoglobulins Phase 2
18 Immune Checkpoint Inhibitors Phase 2
19 Antibodies, Monoclonal Phase 2
20 Antibodies Phase 2
21 Antineoplastic Agents, Immunological Phase 2
22 Albumin-Bound Paclitaxel Phase 2
23 Antimitotic Agents Phase 2
24 Angiogenesis Inhibitors Phase 2
25 Tubulin Modulators Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma Unknown status NCT03022500 Phase 2 durvalumab + tremelimumab
2 Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma Unknown status NCT04224337 Phase 2 Durvalumab + doxorubicin + ifosfamide
3 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
4 A Single-arm Exploratory Clinical Study on the Efficacy and Safety of Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma Recruiting NCT04725448 Phase 2 Toripalimab;Bevacizumab;Nab-paclitaxel;Carboplatin
5 A Phase II, Open-label Study to Evaluate the Efficacy and Safety of HMPL-504 in Locally Advanced/Metastatic MET-Mutation-Positive Pulmonary Sarcomatoid Carcinomas and Other Non-small Cell Lung Cancer Active, not recruiting NCT02897479 Phase 2 Savolitinib
6 Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC) Not yet recruiting NCT04215913

Search NIH Clinical Center for Lung Sarcomatoid Carcinoma

Genetic Tests for Lung Sarcomatoid Carcinoma

Anatomical Context for Lung Sarcomatoid Carcinoma

Organs/tissues related to Lung Sarcomatoid Carcinoma:

MalaCards : Lung, Lymph Node, Spinal Cord, Tongue, Neutrophil, Pineal, Brain

Publications for Lung Sarcomatoid Carcinoma

Articles related to Lung Sarcomatoid Carcinoma:

(show top 50) (show all 261)
# Title Authors PMID Year
1
The Correlation Between Histologic, Immunophenotypic, and Molecular Characteristics of Pulmonary Sarcomatoid Carcinoma Reveals That Sarcomatoid Change Is Potentially Derived From Epithelial Carcinoma Cells Undergoing Epithelial-Mesenchymal Transition. 62
36165833 2023
2
Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report. 62
36471407 2022
3
Analysis of molecular pathologic and clinical features of 36 patients with pulmonary sarcomatoid carcinoma. 62
36447228 2022
4
Factors Associated With Lymph Node Yield and Effects of Lymph Node Density on Survival of Patients With Pulmonary Sarcomatoid Carcinoma. 62
36256867 2022
5
The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: A multicenter retrospective study. 62
36353935 2022
6
Synchronal pulmonary sarcomatoid carcinoma and lung adenocarcinoma EML4-ALK fusion: A case report. 62
36072009 2022
7
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations. 62
36217329 2022
8
Clinical analysis of 78 pulmonary sarcomatoid carcinomas with surgical treatment. 62
36224744 2022
9
Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma. 62
36389311 2022
10
Adjuvant chemotherapy could improve the survival of pulmonary sarcomatoid carcinoma: A systematic review and meta-analysis. 62
35952403 2022
11
Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review. 62
36267791 2022
12
PSC subtyping based on TTF-1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies. 62
35612583 2022
13
Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma. 62
35426613 2022
14
Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma. 62
35954335 2022
15
Lung sarcomatoid carcinoma metastases to the hepatic flexure, the mesenteric and adrenal glands: A case report. 62
35864043 2022
16
Commentary: Resected pulmonary sarcomatoid carcinoma-a defined treatment paradigm, or just the end of the beginning of the search? 62
33812685 2022
17
Adjuvant chemotherapy for pulmonary sarcomatoid carcinoma: A retrospective analysis of the National Cancer Database. 62
33678508 2022
18
Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping. 62
35571650 2022
19
Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024. 62
35092535 2022
20
Pulmonary Sarcomatoid Carcinoma With Epiglottis and Ileum Metastasis Detected by 18F-FDG PET/CT. 62
34653056 2022
21
The treatment of advanced pulmonary sarcomatoid carcinoma. 62
34879738 2022
22
Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report. 62
34953097 2022
23
The Prognosis of Pulmonary Sarcomatoid Carcinoma: Development and Validation of a Nomogram Based on SEER. 62
35730203 2022
24
Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma. 62
34463336 2022
25
A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab. 62
35059287 2022
26
Immunophenotyping of pulmonary sarcomatoid carcinoma. 62
36341325 2022
27
Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study. 62
36339926 2022
28
Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre. 62
36200011 2022
29
Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review. 62
35865468 2022
30
Significant response of pulmonary sarcomatoid carcinoma with obstructive atelectasis to treatment with the PD-1 inhibitor camrelizumab combined with transbronchial cryoablation: A case report and literature review. 62
36387200 2022
31
Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study. 62
36419724 2022
32
MET alterations in advanced pulmonary sarcomatoid carcinoma. 62
36212500 2022
33
Adjuvant chemotherapy is not a decisive factor in improving the overall survival of pulmonary sarcoma: A population-based study. 62
36091171 2022
34
The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma. 62
36389780 2022
35
Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. 62
36324732 2022
36
Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma. 62
35179409 2022
37
Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma. 62
35592676 2022
38
KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients. 62
35359599 2022
39
Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report. 62
35938033 2022
40
Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8+ T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma. 62
35480996 2022
41
Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report. 62
35110965 2022
42
Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art. 62
35368903 2022
43
Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas. 62
34655161 2021
44
Pulmonary sarcomatoid carcinoma mimicking pleural mesothelioma: A case report. 62
34766593 2021
45
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. 62
34166627 2021
46
Savolitinib: First Approval. 62
34455538 2021
47
Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed. 62
35082625 2021
48
Duodenal Metastasis of Pulmonary Pleomorphic Carcinoma: A Case Report. 62
34899244 2021
49
Correction to: GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis. 62
33712881 2021
50
GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis. 62
33570661 2021

Variations for Lung Sarcomatoid Carcinoma

Cosmic variations for Lung Sarcomatoid Carcinoma:

8 (show top 50) (show all 2250)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143166546 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
2 COSM144539293 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
3 COSM106394496 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
4 COSM112509623 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 13
5 COSM128143392 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 13
6 COSM97205442 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 13
7 COSM128342331 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 13
8 COSM142955742 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
9 COSM146194764 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
10 COSM147030479 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
11 COSM128500813 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 13
12 COSM97165521 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
13 COSM105692110 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
14 COSM107300017 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
15 COSM97173559 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
16 COSM142535359 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
17 COSM146259120 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
18 COSM127348533 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 13
19 COSM118539070 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
20 COSM126890772 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 13
21 COSM128632965 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.283G>T p.V95L 6:43777633-43777633 13
22 COSM88794233 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
23 COSM84939935 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.199G>T p.V67L 6:43777633-43777633 13
24 COSM97138403 VEGFA lung,NS,carcinoma,sarcomatoid carcinoma c.823G>T p.V275L 6:43777633-43777633 13
25 COSM131095609 TSHR lung,NS,carcinoma,sarcomatoid carcinoma c.2082C>G p.S694R 14:81144140-81144140 13
26 COSM85479420 TSHR lung,NS,carcinoma,sarcomatoid carcinoma c.2082C>G p.S694R 14:81144140-81144140 13
27 COSM93231483 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.490A>T p.K164* 17:7675122-7675122 13
28 COSM93189061 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.782+1G>T p.? 17:7674180-7674180 13
29 COSM143415517 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.373A>T p.K125* 17:7675122-7675122 13
30 COSM112289613 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.482C>A p.A161D 17:7675130-7675130 13
31 COSM144046484 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.449C>A p.A150D 17:7675130-7675130 13
32 COSM106053037 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.659A>G p.Y220C 17:7674872-7674872 13
33 COSM143943655 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.182A>G p.Y61C 17:7674872-7674872 13
34 COSM122739428 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.386+1G>T p.? 17:7674180-7674180 13
35 COSM143187727 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.5C>A p.A2D 17:7675130-7675130 13
36 COSM121875754 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.263A>G p.Y88C 17:7674872-7674872 13
37 COSM144310046 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.542A>G p.Y181C 17:7674872-7674872 13
38 COSM144650895 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.542A>G p.Y181C 17:7674872-7674872 13
39 COSM112258683 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.782+1G>T p.? 17:7674180-7674180 13
40 COSM145050841 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.365C>A p.A122D 17:7675130-7675130 13
41 COSM142874218 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.490A>T p.K164* 17:7675122-7675122 13
42 COSM144013214 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.626A>G p.Y209C 17:7674872-7674872 13
43 COSM122772989 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.86C>A p.A29D 17:7675130-7675130 13
44 COSM106089182 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.482C>A p.A161D 17:7675130-7675130 13
45 COSM143370705 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.542A>G p.Y181C 17:7674872-7674872 13
46 COSM144114793 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.5C>A p.A2D 17:7675130-7675130 13
47 COSM144338406 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.365C>A p.A122D 17:7675130-7675130 13
48 COSM144348052 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.373A>T p.K125* 17:7675122-7675122 13
49 COSM122784424 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.94A>T p.K32* 17:7675122-7675122 13
50 COSM111795092 TP53 lung,NS,carcinoma,sarcomatoid carcinoma c.482C>A p.A161D 17:7675130-7675130 13

Expression for Lung Sarcomatoid Carcinoma

Search GEO for disease gene expression data for Lung Sarcomatoid Carcinoma.

Pathways for Lung Sarcomatoid Carcinoma

Pathways related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1 13.65 RET MET KRAS KDM4C HRAS EGFR
2
Show member pathways
13.21 ALK EGFR EML4 HRAS KRAS MET
3
Show member pathways
13.19 ROS1 MET KRAS HRAS EGFR ALK
4
Show member pathways
13.13 ALK EGFR HRAS KRAS MET ROS1
5 12.56 ALK CD274 EGFR HRAS KRAS MET
6
Show member pathways
12.53 KRAS HRAS EML4 EGFR ALK
7
Show member pathways
12.29 MET KRAS HRAS EGFR
8 12.09 MET KRAS HRAS EGFR
9
Show member pathways
12.08 ROS1 MET KRAS HRAS EGFR ALK
10
Show member pathways
12.07 MET KRAS HRAS EGFR
11
Show member pathways
11.92 KRAS HRAS EGFR
12 11.85 KRAS HRAS EGFR
13
Show member pathways
11.85 KRAS HRAS EGFR
14 11.82 ROS1 RET MET EGFR ALK
15
Show member pathways
11.77 KRAS HRAS EGFR
16
Show member pathways
11.64 RET KRAS HRAS
17 11.6 KRAS HRAS EGFR
18 11.47 KRAS HRAS EGFR
19 11.3 KRAS HRAS EGFR
20 11.26 KRAS HRAS EGFR
21 11.2 KRAS HRAS EGFR
22 11.2 MET HRAS EGFR
23 11.14 RET MET HRAS EGFR
24 11.09 KRAS HRAS EGFR
25
Show member pathways
11.01 KRAS HRAS EGFR
26 10.79 HRAS EGFR
27 10.7 MET KRAS HRAS EGFR
28 10.68 ROS1 MET KRAS HRAS EML4 ALK
29
Show member pathways
10.67 KRAS HRAS

GO Terms for Lung Sarcomatoid Carcinoma

Cellular components related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.32 ROS1 RET MET EGFR ALK

Biological processes related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.97 RET KRAS HRAS EGFR
2 peptidyl-tyrosine phosphorylation GO:0018108 9.91 ROS1 RET MET EGFR ALK
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.85 ALK EGFR MET RET ROS1
4 peptidyl-tyrosine autophosphorylation GO:0038083 9.72 ROS1 EGFR ALK
5 positive regulation of kinase activity GO:0033674 9.65 ROS1 RET MET EGFR ALK
6 multicellular organism development GO:0007275 9.02 ROS1 RET MET EGFR ALK

Molecular functions related to Lung Sarcomatoid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.65 ROS1 RET MET EGFR ALK
2 protein kinase activity GO:0004672 9.55 ROS1 RET MET EGFR ALK
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.32 ROS1 RET MET EGFR ALK

Sources for Lung Sarcomatoid Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....